Skip navigation
Please use this identifier to cite or link to this item: https://repositorio.unb.br/handle/10482/42134
Files in This Item:
File Description SizeFormat 
ARTIGO_PrevalenceDermatologicalToxicities.pdf2,95 MBAdobe PDFView/Open
Title: Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy : systematic review and meta-analysis
Authors: Garrett, Náthali Felícia Mineiro dos Santos
Costa, Ana Cristina Carvalho da
Ferreira, Elaine Barros
Damiani, Giovanni
Reis, Paula Elaine Diniz dos
Vasques, Christiane Inocêncio
metadata.dc.identifier.orcid: https://orcid.org/0000-0003-4799-6880
https://orcid.org/0000-0001-9586-9486
Assunto:: Erupções
Toxicidade
Prurido
Vitiligo
Eritema
Melanoma
Quimioterapia
Issue Date: 6-Aug-2021
Publisher: Plos One
Citation: GARETT, Náthali Felícia Mineiro dos Santos et al. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis. PLoS ONE, v. 16, n. 8, e0255716, 2021. DOI: https://doi.org/10.1371/journal.pone.0255716. Disponível em: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255716. Acesso em: 13 out. 2021.
Abstract: Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated. Objective To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy. Materials and methods We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data Results A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%). Conclusion The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.
Licença:: Copyright: © 2021 Mineiro dos Santos Garrett et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI: https://doi.org/10.1371/journal.pone.0255716
Appears in Collections:ENF - Artigos publicados em periódicos

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/42134/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.